Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. Under the terms of the agreement, Personalis will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia (CLL) patients enrolled in a Phase II clinical trial assessing the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptase (hTERT) protein, as monotherapy or in combination with ibrutinib.
“Personalis is known for their innovative and expansive cancer immunogenomics expertise, and we’re delighted to partner with them on this project to evaluate biomarker signatures in responders and non-responders to our leading cancer vaccine candidate, INVAC-1,” said Pierre Langlade Demoyen, CEO of Invectys. “INVAC-1 has the potential to become a key component of combination therapy approaches for the treatment of various solid and hematologic cancer types. Our work with Personalis will help us to determine which patients are most likely to respond favorably to these novel treatment regimens.”
Invectys is now enrolling CLL patients in this Phase II, open-label, single-arm trial consisting of two patient groups: 45 patients receiving INVAC-1 as monotherapy and an additional 45 patients receiving INVAC-1 in combination with ibrutinib, a Bruton's Tyrosine Kinase inhibitor. The primary goal of the study is to achieve minimal residual disease negativity in both groups. The trial is being conducted at the MD Anderson Cancer Center in Houston, Texas. For more information, please visit clinicaltrials.gov identifier NCT03265717.
“Invectys has built an exciting pipeline of novel, next-generation immunotherapies, and we’re thrilled to help drive their lead program forward,” said John West, CEO of Personalis. “Having already established ourselves as a leader in comprehensive tumor immunogenomic profiling and biomarker discovery for solid tumor indications, we’ve seen increasing use of our capabilities for biomarker evaluation in hematologic cancer types. This bodes well as we continue to rollout and onboard customers for our newly-launched, universal cancer immunogenomics platform, ImmunoID NeXT™.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Founded in 2010 at the Pasteur Institute in Paris, Invectys SA is a biopharmaceutical company focused on the development of innovative immuno-oncology treatments. Invectys has raised €38 million. The company has developed a broad pipeline including one platform designed to provide low-cost, easy-to-administer cancer therapies, alone or in combination with other treatments such as immune checkpoint antibodies. Invectys products aim to enlist and restore natural antitumor efficacy in cancer patients.
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the development as INVAC-1 as a treatment for solid and hematologic cancer types; and the use and adoption of ImmunoID NeXT™. These forward-looking statements are subject to risks and uncertainties, including those discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kanguru Leaps Over The Competition With A New OS Agnostic Encrypted Fingerprint Access Flash Drive5.12.2019 19:31:00 EET | Press release
Kanguru is proud to announce the launch of the world’s first OS Agnostic, Fingerprint Access Hardware Encrypted Flash Drive with remote management capability. This new biometric fingerprint access flash drive supplants the bulky pinpads and fussy combo keypads of leading encrypted devices, making it much more convenient and easy to use. With just a tap of the finger, the new Kanguru Defender Bio-Elite30™ Fingerprint Hardware Encrypted Flash Drive provides quick access to encrypted files. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005662/en/ The New Kanguru Defender Bio-Elite30 Fingerprint Hardware Encrypted Flash Drive is OS Agnostic, remotely manageable, and provides best-in-class encryption with easy fingerprint access! (Photo: Business Wire) Being OS Agnostic, the Defender Bio-Elite30 can be used on virtually any machine, from Windows and MacOS, to medical equipment, smart TVs and even ATMs for making bank machi
Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies5.12.2019 17:00:00 EET | Press release
Sensor Electronic Technology, Inc. (“SETi”), a leading global innovator of deep UV LED products and technology, announced that it successfully obtained a permanent injunction in a patent infringement lawsuit against Bolb, Inc. (“Bolb”), and Quantum Egg, Inc. (“Q-Egg”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005031/en/ The history of UV LED business (Graphic: Business Wire) The California Northern District federal court issued a permanent injunction against the sales of an accused UV LED sterilizer device, as well as any mere colorable variations, according to the parties’ stipulation. The Court will therefore prohibit the sale of similar products if they prove to be mere colorable variations of the accused products. The asserted patents in this litigation cover fundamental UV LED technology, encompassing UV LED sterilizer structures and drivers, chip fabrication, and epitaxial layer growth. Bolb is a UV LED com
SHRM--Society for Human Resource Management and Prometric Renew Long-Term Partnership with Multi-year Agreement5.12.2019 17:00:00 EET | Press release
Following a comprehensive procurement process, we’re excited to announce that SHRM--Society for Human Resource Management®, the voice of all things work, has selected Prometric® as its strategic testing partner. Under the renewal, Prometric will assist in the delivery of the SHRM Certified Professional (SHRM-CP®) and SHRM Senior Certified Professional (SHRM-SCP®) exam programs—the global certification standard for the HR profession. This agreement extends the partnership between the organizations that started in 2010. Since inception of the certification program in 2014, Prometric has partnered with SHRM to deliver more than 75,000 exams globally with over 90% growth since the first administration. With businesses increasingly recognizing that effective people management is a strategic imperative, leaders now expect HR professionals to also demonstrate the behavioral competencies required to effectively apply knowledge in the modern workplace. By incorporating key HR competencies and k
Sartorius Acquires a Majority Stake in Cell Culture Media Specialist Biological Industries5.12.2019 16:19:00 EET | Press release
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, signed an agreement to acquire a majority stake in the Israeli cell culture media developer and manufacturer Biological Industries. For approximately €45 million in cash, Sartorius is acquiring just over 50% of the shares of the company from its owners, Kibbutz Beit Haemek and private equity fund Fortissimo Capital. An option to acquire a further 20% of the shares within three years was also agreed. The transaction is subject to customary closing conditions and expected to be finalized by mid-December. “By acquiring a majority stake in Biological Industries, we are significantly expanding our cell culture media offering and complementing our product portfolio for customers in the dynamically growing advanced therapies market,” commented Joachim Kreuzburg, CEO of the Sartorius Group. Biological Industries focuses on cell culture media, particularly for cell and gene therapy, regenerat
PW Power Systems Delivers Brighter Holidays for Puerto Rico5.12.2019 16:06:00 EET | Press release
PW Power Systems (PWPS), the leading provider of aero-derivative power generation energy solutions, announces that PREPA (Puerto Rico Electric Power Authority) has three, PWPS FT8® MOBILEPAC® gas turbines ready for operation. The 30-megawatt mobile gas turbine units are now available for emergency power, as well as for grid security in support of Puerto Rico’s environmental sustainability plan. PWPS supported ARG Precision Corporation, which completed the turnkey installation of the FT8 MOBILEPAC dual-fuel capacity gas turbines at the Palo Seco Power Plant in Toa Baja. Puerto Rico Governor Wanda Vazquez said, “The three generators provide the opportunity for fast response in the event of an emergency or situation where we lose energy in the metropolitan area. In eight to ten minutes we can energize the system and provide electricity to about 40,000 customers. Critical services such as hospitals in the metropolitan area will also have that security.” “The three mega-generators can meet
Odaseva Announces Significant Enhancements to Its Data Governance Platform for Salesforce Users5.12.2019 16:00:00 EET | Press release
Odaseva, the award-winning unified cloud data compliance, protection, and operations platform for enterprises running Salesforce as a business-critical application, today announced several new enhancements to its platform including increased compliance automation applications as well as support for the Salesforce Marketing Cloud and Ultra High Availability for Salesforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005216/en/ (Graphic: Business Wire) Updated Compliance Applications for Enhanced Regulation Coverage For the past few years, Odaseva has offered users the ability to automate their data compliance and privacy activities for the General Data Protection Regulation (GDPR). This has allowed organizations to reduce financial, regulatory and reputational risk by automating their compliance activities – utilizing such Odaseva tools as Sandbox Anonymization and Production Data Lifecycle. Now, Odaseva has increase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom